White blood cells disorders involving a specific type of white blood cell include:
Neutropenia. Neutropenia (noo-troe-PEE-nee-uh) is a low number of neutrophils, a type of white blood cell that fights infections of fungi and bacteria. Neutropenia can be caused by cancer or by diseases, disorders or infections that damage bone marrow. In addition, certain medications and other diseases or conditions can cause neutropenia.
Lymphocytopenia. Lymphocytopenia (lim-foe-sie-toe-PEE-nee-uh) is a decrease in lymphocytes, the type of white blood cell that, among other tasks, protects your body from viral infections. Lymphocytopenia can result from an inherited syndrome, be associated with certain diseases, or be a side effect from medications or other treatments.
Monocyte disorders. Monocytes help get rid of dead or damaged tissue and regulate your body’s immune response. Infections, cancer, autoimmune diseases and other conditions can cause an increased number of monocytes. A decreased number can be the result of toxins, chemotherapy and other causes.
Eosinophilia. Eosinophilia (e-o-sin-o-FIL-e-uh) is a higher than normal number of eosinophil cells, a type of disease-fighting white blood cell. Eosinophilia can be caused by a variety of conditions and disorders, most commonly by an allergic reaction or a parasitic infection.
Basophilic disorders. Basophils account for only a small number of white blood cells, but they have a role in wound healing, infection and allergic reactions. A decreased number of basophils can result from high thyroid hormone levels, allergic reactions or infections. An increased number can be caused by certain types of blood cancer, low thyroid hormone levels or other disorders.
Like Ariana-Leilani, Oliver Bayliss of the UK has a rare blood disorder. Suffering from Severe Neutropenia condition meant that he was susceptible to infections as his blood was deficient in white blood cells and unable to fight bacteria. It is quite a rare condition and his parents, Paul and Sharon Bayliss, only know of two other families in the UK that have similar problems.
Teva UK Limited has today launched Lonquex® (lipegfilgrastim) in the UK. Lonquex® is indicated for the reduction of the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
Lonquex® is a new long-acting recombinant granulocyte colony-stimulating factor (G-CSF) with the active ingredient lipegfilgrastim – a novel glycoPEGylated (PEG; polyethylene glycol) filgrastim molecule. Lonquex® is intended as a once per cycle fixed dose, subcutaneous injection for neutrophil support in cancer patients receiving myelosuppresive chemotherapy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
The UK launch is part of a Europe-wide market launch of the medicine, and it has already been launched in several European markets, including Germany, the Netherlands and Ireland.
Medscape News published a list of the top selling drugs in the United States based on a list produced by IMS Health. Amgen’s Neulasta, a long acting form of neupogen for the treatment of neutropenia (the treatment denied but needed by Ariana-Leilani), made tenth place at $3.6 billion in annual sales. Read more at Medscape
A study involving 167 patients was published in the December 1 issue of the Journal of Clinical Oncology and reported that when the use of prophylactic granulocyte-colony stimulating factor (G-CSF) to reduce febrile neutropenia (FN) was decreased in patients receiving chemotherapy for breast cancer, it led to a more than 5-fold increase in FN episodes and an early end to the clinical trial.
In an accompanying study, Dr. Aarts’s research team evaluated the cost effectiveness of pegfilgrastim prophylaxis for FN. They conclude that skipping G-CSF after the first 2 chemo cycles saved an average of €3491 per patient. They estimate that nationwide, this would translate into a saving of €14.3 million each year.
However, this resulted in an unexpected and substantial increase in FN incidence. The researchers calculate that the incremental cost-effectiveness ratio for preventing an FN episode by giving G-CSF with every chemotherapy cycle, compared with only for the first 2 cycles, worked out to €13,112 per patient.
“When one is willing to pay at least €13,122 per patient with FN episodes prevented, 6 cycles of G-CSF prophylaxis is considered a cost-effective strategy,” they conclude.
The Save Ariana-Leilani Coalition is pleased to announce the world wide release of the video documentary “Small Cries.” The six minute documentary tells the story of how the “child protection” systems in the United States are failing, and how Ariana-Leilani is a victim of that failure. This short and compelling documentary features exclusive interviews, including an interview with Dr. Joy Silberg, who speaks of the error in judgment that many child protective services make in certain abuse and neglect cases. Very educational and inspiring, and Ireneo Namboka, an international human rights advocate and former UN official.
Definitely a “two thumbs up” “must see” documentary.
Watch the video, sign the petition, save a life:
Documentary “Small Cries;” The Real Ariana-Leilani Story
Dutch team is recommending the continued use of primary granulocyte colony-stimulating factor (G-CSF) prophylaxis throughout all chemotherapy cycles in women with early breast cancer who are at high risk of febrile neutropenia (FN). At present, the approach is standard practice in this population.
In an interview on the Jay Leno show, President Obama stated:
Well, I’ve been very clear that when it comes to universal rights, when it comes to people’s basic freedoms, that whether you are discriminating on the basis of race, religion, gender or sexual orientation, you are violating the basic morality that I think should transcend every country. And I have no patience for countries that try to treat gays or lesbians or transgender persons in ways that intimidate them or are harmful to them.
Doesn’t 10 Year Old Ariana-Leilani, who lives in Washington DC’s Ward 3, have a right to life saving medical care? Stop the discrimination against Ariana-Leilani. Let’s stop the violation of her rights.
Click to read the 2011 Letter to Mayor Vince Gray About Ariana-Leilani’s Plight
Ariana-Leilani lives in the Palisades Section, Ward 3, of Washington DC. When the German government wrote to the US State Department begging them to come to the aid of Ariana-Leilani, the US State Department turned that request over the the District of Columbia because the US State Department believed that the District of Columbia had the authority to take action. Despite the fact that Ariana-Leilani goes to the Francis Scott Key School (Dana Place) in the DC Public School system, Washington DC — under the “leadership” of Mayor Vince Gray — has refused to take any action claiming itself to be a toothless tiger — claiming it lacked authority to do anything. (Read the letter to Mayor Vince Gray Concerning the plight of Ariana-Leilani)
Mayor Gray’s regrettable attitude has made many sorry they supported his election to the post of Mayor. Washington DC has, unfortunately, become a cesspool of child abuse, with a CPS that is so incompetent that it has been under federal court monitor for over 20 years, and has been run by individuals, like Roque Gerald and James Toscano, with sex offense records.
President Obama courageously stated yesterday that his experience 35 years ago with discrimination were similar to those experienced by Trayvon Martin and other African-American’s like him now. Ariana-Leilani is African-American, and her case highlights the second class treatment of children like her in the District of Columbia. Its time for Ariana-Leilani to get life saving medicine and medical attention that she deserves. Speak up for her, because she is not allowed to speak up for herself:
Make sure she gets the help she needs before it is too late.